Pharmaceutical Chemistry Journal

, Volume 47, Issue 12, pp 655–659 | Cite as

Synthesis and Neurotropic Activity of 8-Amino Derivatives of Condensed Thieno[3,2-d]- and Furo[3,2-d]Pyrimidines

  • S. N. Sirakanyan
  • A. A. Ovakimyan
  • A. S. Noravyan
  • N. S. Minasyan
  • I. A. Dzhagatspanyan
  • I. M. Nazaryan
  • A. G. Akopyan
Article
First Online:
Received:

New derivatives of pyrano[4″,3″:4′,5′]pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidines based on 3-chloro derivatives of pyrano[3,4-c]pyridines and pyrano[4″,3″:4′,5′]pyrido[3′,2′:4,5]furo[3,2-d]pyrimidines based on previously prepared 8-chloro derivatives were synthesized. Studies of the biological activity of the synthesized compounds showed that several of them exhibited neurotropic properties.

Keywords

pyrano[3,4-c]pyridines thieno[3,2-d]pyrimidines furo[3,2-d]pyrimidines cyclization amino derivatives neurotropic activity 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    A. Agarwal, S. Louise-May, A. J. Thanassi, et al., Bioorg. Med. Chem. Lett., 17, 2807 – 2810 (2007).PubMedCrossRefGoogle Scholar
  2. 2.
    M. Hayakawa, H. Kaizawa, H. Moritomo, et al., Bioorg. Med. Chem. Lett., 17, 2438 – 2442 (2007).PubMedCrossRefGoogle Scholar
  3. 3.
    S. N. Sirakanyan, E. G. Paronikyan, and A. S. Noravyan, Nitrogenous Heterocycles and Alkaloids [in Russian], Iridium Press, Moscow (2001), pp. 527 – 529.Google Scholar
  4. 4.
    S. N. Sirakanyan, A. A. Ovakimyan, S. N. Noravyan, et al., Khim.-farm. Zh., 47(3), 8 – 11 (2013).Google Scholar
  5. 5.
    S. N. Sirakanyan, E. G. Paronikyan, and A. S. Noravyan, Khim. Geterotsikl. Soedin., 3, 421 – 425 (2003).Google Scholar
  6. 6.
    S. N. Sirakanyan, A. A. Ovakimyan, and A. S. Noravyan, Khim. Zh. Arm., 64(3), 401 – 410 (2011).Google Scholar
  7. 7.
    S. N. Sirakanyan, E. G. Paronikyan, M. S. Gukasyna, et al., Khim. Geterotsikl. Soedin., 6, 912 – 918 (2010).Google Scholar
  8. 8.
    H. G. Vogel and W. H. Vogel (eds.), Drug Discovery and Evaluation. Pharmacological Assays, Springer, Berlin and New York (1997), pp. 246 – 350.Google Scholar
  9. 9.
    A. P. Mkrtchyan, S. G. Kazaryan, A. S. Noravyan, et al., Khim.-farm. Zh., 32(9), 15 – 19 (1998).Google Scholar
  10. 10.
    I. A. Dzhagatspanyan and A. B. Asryan, Eksp. Klin. Farmakol., No. 1, 5 – 8 (1994).Google Scholar
  11. 11.
    G. Dawson and M. D. Tricklebank, Trends Pharmacol. Sci., 16, 33 – 36 (1995).PubMedCrossRefGoogle Scholar
  12. 12.
    S. E. File, Behav. Brain Res., 58, 199 – 202 (1993).PubMedCrossRefGoogle Scholar
  13. 13.
    A. Covanis, A. Gupta, and P. Jeavons, Epilepsia, 23, 693 – 720 (1982).PubMedCrossRefGoogle Scholar
  14. 14.
    T. Ketter, R. Post, and W. Theodore, Neurology, 53 (Suppl. 2), 53 – 67 (1999).Google Scholar
  15. 15.
    W. Lusher, Valproate, W. Lusher (ed.), Birkhanser, Basel, Boston (1999), pp. 37 – 45.Google Scholar
  16. 16.
    J. Bures and O. Buresova, J. Comp. Physiol. Psychol., 56, 268 – 272 (1963).CrossRefGoogle Scholar
  17. 17.
    A. V. Kaluev and N. A. Nutsa, Eksp. Klin. Farmakol., No. 5, 69 – 74 (1998).Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • S. N. Sirakanyan
    • 1
  • A. A. Ovakimyan
    • 1
  • A. S. Noravyan
    • 1
  • N. S. Minasyan
    • 2
  • I. A. Dzhagatspanyan
    • 1
  • I. M. Nazaryan
    • 1
  • A. G. Akopyan
    • 1
  1. 1.Mndjoyan Institute of Fine Organic Chemistry, Scientific and Technological Center of Organic and Pharmaceutical ChemistryNational Academy of Sciences of ArmeniaYerevanArmenia
  2. 2.Molecular Structure Research Center, Scientific and Technological Center of Organic and Pharmaceutical ChemistryNational Academy of Sciences of ArmeniaYerevanArmenia

Personalised recommendations